Budapest, Hungary - Turbine, a pioneering biotechnology research company, announced today the successful completion of its Series A funding round, raising an impressive $6,004,625. The investment was led by MassMutual Ventures, a renowned venture capital firm focused on supporting innovative healthcare technologies and solutions.

Turbine was established with a clear mission in mind: to gain a comprehensive understanding of complex cancers surpassing existing experimental tools and address unmet oncology needs. Through the convergence of computer science and molecular biology, combined with the world's most intricate simulation of cell behavior, Turbine is revolutionizing cancer research and treatment.

The company's groundbreaking platform, the Simulated Cell™, serves as the cornerstone of Turbine's approach. Leveraging this platform, Turbine uncovers novel biological insights across both established and unexplored cancer targets, addressing the 70% of cancers that currently lack thorough investigation. By providing a fresh biological context, defining responsive patient populations, and designing drug combination approaches to mitigate resistance, Turbine aims to unlock new avenues for precision therapeutics.

Turbine's success is underpinned by a rigorous process, validated by its clinical stage predictions, and bolstered by a proprietary pipeline. These factors contribute to Turbine's ability to develop next-generation precision therapeutics that hold the potential to transform cancer treatment paradigms.

"We are thrilled to have secured this significant investment from MassMutual Ventures," said Szabolcs Nagy, Founder of Turbine. "This funding will enable us to continue pushing the boundaries of cancer research and unlock critical insights into complex cancers that have eluded scientific understanding. We are confident that our unique approach, powered by the Simulated Cell™ platform, will pave the way for the development of novel precision therapeutics with the potential to transform the lives of cancer patients."